Zoetis
Zoetis is a United States-based animal-health company that develops medicines, vaccines, diagnostics, and related services for companion animals and livestock.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Zoetis is a global animal-health company whose principal business is the discovery, development, manufacture, and marketing of medicines, vaccines, diagnostic products, genetic services, and other technologies for veterinary use. Its customers include veterinarians, livestock producers, animal-health distributors, and pet owners reached through veterinary channels. The company serves both companion animals, especially dogs and cats, and production animals such as cattle, swine, poultry, fish, and sheep. The business grew out of Pfizer's animal-health operations. Pfizer began researching veterinary applications of medicines in the 1950s, including oxytetracycline for livestock, and established the Vigo research and development site in Terre Haute, Indiana, in 1952. Pfizer's agriculture business was later renamed Pfizer Animal Health. Through acquisitions and internal development, that division expanded from livestock medicines into companion-animal pharmaceuticals, vaccines, diagnostics, genetics, and biologic therapies. The acquisition of Norden Laboratories in 1995 was particularly important in broadening Pfizer's small-animal portfolio. Zoetis was created as an independent corporate identity during Pfizer's separation of its animal-health business. Pfizer filed for the company's public offering in 2012, and Zoetis completed its initial public offering in February 2013. Pfizer initially retained majority control, but in June 2013 Pfizer distributed its remaining interest to its shareholders, completing the separation. Zoetis subsequently operated as an independent public company and joined the S&P 500 in 2013. The company's portfolio includes parasiticides, dermatology treatments, pain and anti-inflammatory medicines, anti-infectives, vaccines, reproductive products, livestock therapeutics, aquaculture treatments, diagnostics, and animal-genetics offerings. Products such as Apoquel, Cytopoint, Simparica, Revolution, Rimadyl, Convenia, and a wide range of livestock vaccines and treatments have helped make Zoetis a prominent supplier to veterinary practices. Its strategy has increasingly emphasized chronic and preventive care in pets, species-specific biologics, diagnostics, precision livestock technologies, and products that improve animal productivity and welfare. Zoetis has expanded through acquisitions as well as organic research. Transactions involving Fort Dodge Animal Health, Synbiotics, Pharmaq, Nexvet, KL Automation, Abaxis, Jurox, Basepaws, and PetMedix added capabilities in vaccines, aquaculture, diagnostics, robotics, genetics, and antibody-based therapies. The company has also maintained a multinational manufacturing and research network, with facilities designed to meet regulatory requirements for pharmaceutical and biologics production. Zoetis directly markets products in approximately 45 countries and sells them in more than 100 countries. International operations are a substantial part of its business, and its products are distributed through veterinary and agricultural channels worldwide. The company remains focused exclusively on animal health rather than human pharmaceuticals, distinguishing it from its former parent Pfizer and from diversified healthcare companies. In 2025, the United States Department of Agriculture granted conditional approval for deployment of a Zoetis poultry vaccine in the context of the national highly pathogenic avian influenza response, illustrating the company's role in emergency animal-disease preparedness as well as routine veterinary care.
History
Zoetis traces its origins to Pfizer's veterinary research and agricultural business. During the 1950s, Pfizer investigated medicines for livestock, including oxytetracycline, and in 1952 opened the Vigo research and development facility in Terre Haute, Indiana. The agricultural division developed into Pfizer Animal Health and gradually broadened its remit from livestock treatments to a full animal-health portfolio. A major early expansion came in 1995, when Pfizer acquired Norden Laboratories from GlaxoSmithKline. That transaction strengthened Pfizer's small-animal business and gave it a larger presence in medicines for dogs and cats. During the 2000s and early 2010s, Pfizer added further capabilities through acquisitions including Embrex, Catapult Genetics, Bovigen, Wyeth, Fort Dodge Animal Health, Vetnex Animal Health, Synbiotics, Microtek, King Pharmaceuticals, and Alpharma. These transactions contributed products and expertise in vaccines, genetics, diagnostics, biologics, and livestock therapeutics. Pfizer formally announced plans to separate its animal-health operation in 2012. The new company was named Zoetis, a name derived from a Greek-related term associated with life. Pfizer filed registration documents for a Zoetis public offering in August 2012. On February 1, 2013, Zoetis sold 86.1 million shares in its initial public offering. Pfizer retained an approximately 83 percent interest at the time, while the offering proceeds were used in part to reduce Pfizer debt. The IPO was one of the largest United States corporate offerings of its period. The separation was completed in June 2013, when Pfizer distributed its retained Zoetis interest to Pfizer shareholders. Zoetis became an independent animal-health company and was added to the S&P 500. Its business model combined a broad commercial portfolio with research, manufacturing, and regulatory operations across multiple regions. The company marketed directly in dozens of countries and distributed products in many more through commercial partners. After independence, Zoetis continued to build scale through targeted acquisitions. In 2014 it purchased a portfolio of pet medicines from Abbott Laboratories. In 2015 it agreed to acquire Pharmaq, giving it a stronger position in aquaculture health. In 2017 it acquired Nexvet, a developer focused on biologics and antibody-based veterinary therapies, and KL Automation. In 2018 it announced the acquisition of Abaxis, bringing veterinary diagnostic instruments and testing technology into its portfolio. The company later expanded into additional technologies and geographic markets. In 2021 it announced the purchase of Jurox, an Australian animal-health company with operations and products serving markets including New Zealand, the United States, Canada, and the United Kingdom. In 2022 it acquired Basepaws, a genetics company focused on cats. In 2023 it acquired PetMedix, a Cambridge-based biotechnology company working on species-specific antibody therapies for companion animals. Zoetis's modern portfolio spans companion-animal medicines, livestock medicines, vaccines, parasiticides, dermatology treatments, pain management, anti-infectives, diagnostics, animal genetics, reproductive technologies, and aquaculture products. Its manufacturing network includes facilities in multiple countries, and some research and manufacturing activities are colocated to support product development and production. The company has increasingly emphasized chronic pet conditions, preventive medicine, biologics, precision livestock production, and diagnostic information. The company's international reach is central to its identity. Zoetis directly markets in approximately 45 countries and sells products in more than 100. Operations outside the United States have represented a significant share of its business. In 2025, amid a severe United States avian-influenza outbreak, the USDA granted conditional approval for a Zoetis poultry vaccine, placing the company within a wider national effort to prepare and respond to animal disease threats. Zoetis remains an independent, publicly traded specialist in animal health rather than a human-pharmaceutical subsidiary.
- 2025
Conditional approval for a poultry avian-influenza vaccine
[1]The USDA granted conditional approval for Zoetis to deploy a poultry vaccine during the United States avian-influenza response.
- 2023
Zoetis acquires PetMedix
[1]The acquisition strengthened Zoetis's work in species-specific antibody therapies for companion animals.
- 2022
Zoetis acquires Basepaws
[1]The acquisition added cat-focused genetics and related data capabilities.
- 2021
Zoetis announces the acquisition of Jurox
[1]Jurox broadened Zoetis's presence in Australia and other livestock and companion-animal markets.
- 2018
Zoetis announces the Abaxis acquisition
[1]The proposed cash acquisition added a major veterinary diagnostics platform to Zoetis.
- 2015
Zoetis agrees to acquire Pharmaq
[1]The transaction expanded Zoetis's aquaculture-health business.
- 2013
Zoetis completes its initial public offering
[1]Zoetis sold 86.1 million shares in its IPO, with Pfizer initially retaining majority control.
- 2013
Zoetis becomes independent from Pfizer
[1]Pfizer distributed its remaining interest to shareholders, completing the separation of Zoetis as an independent public company.
- 2012
Pfizer announces the creation of a separate animal-health company
[1]Pfizer announced plans to separate Pfizer Animal Health and filed registration documents for the future company's public offering.
- 1995
Pfizer acquires Norden Laboratories
[1]The acquisition expanded Pfizer's animal-health activities into small-animal care and strengthened its companion-animal portfolio.
Products and positioning
A science-led, global animal-health specialist serving both companion-animal medicine and livestock production, with an emphasis on preventive care, diagnostics, vaccines, parasiticides, chronic disease management, biologics, and productivity technologies.
Companion-animal dermatology
Apoquel
A prescription treatment for allergic and atopic skin disease in dogs. It is one of Zoetis's best-known companion-animal products and represents the company's focus on veterinary dermatology and recurring pet-care needs.
Companion-animal biologic
Cytopoint
A biologic therapy used by veterinarians to manage allergic itch associated with canine atopic dermatitis. Its species-specific antibody approach illustrates Zoetis's expansion beyond conventional small-molecule medicines.
Companion-animal parasiticide
Simparica
A dog parasiticide brand used for protection against specified external and internal parasites, depending on the product variant and market. It is part of Zoetis's preventive-care portfolio for companion animals.
Companion-animal parasiticide
Revolution
A veterinary parasiticide brand sold for companion animals. Product indications vary by species and country, but the line is associated with preventive parasite control in dogs and cats.
Veterinary pain and anti-inflammatory medicine
Rimadyl
A carprofen-based veterinary brand used for pain and inflammation management in dogs. It is an established part of Zoetis's companion-animal therapeutics portfolio.
Veterinary anti-infective
Convenia
An injectable veterinary antibiotic brand used in appropriate canine and feline indications under veterinary supervision. It addresses the practical need for long-acting treatment in clinical settings.
Livestock vaccine
Bovilis
A family of livestock vaccines used in cattle and other production-animal settings, with specific formulations and indications varying by market. The brand represents Zoetis's preventive approach to herd health.
Veterinary diagnostics
Abaxis veterinary diagnostics
Diagnostic analyzers and related systems brought into Zoetis through its acquisition of Abaxis. These tools support in-clinic testing and help veterinarians make treatment and monitoring decisions.
Brand decisions
2025
Support emergency poultry disease preparednessOtherBackground
The United States faced a significant highly pathogenic avian-influenza outbreak affecting poultry and some people exposed through animal contact.
Action taken
The USDA granted conditional approval for deployment of a Zoetis poultry vaccine.
Aftermath
The approval positioned the vaccine for limited-duration emergency use while authorities continued evaluating disease-control measures and vaccine-stockpile needs.
2023
Acquire PetMedixM&ABackground
Zoetis was expanding its biologics platform and seeking more species-specific therapies for companion animals.
Action taken
Zoetis acquired PetMedix, a United Kingdom biotechnology company focused on antibody therapies.
Aftermath
The acquisition added research and development capabilities in species-specific companion-animal biologics.
2018
Acquire AbaxisM&ABackground
Veterinary diagnostics were becoming increasingly important to clinical decision-making and recurring practice revenue.
Action taken
Zoetis announced a cash acquisition of Abaxis and its veterinary diagnostic technology.
Aftermath
The transaction integrated diagnostic instruments and testing capabilities into Zoetis's animal-health platform.
Announced transaction value. approximately US$1.9 billion (May 2018)
2015
Acquire PharmaqM&ABackground
Zoetis sought to expand beyond terrestrial companion-animal and livestock medicines into aquaculture health.
Action taken
The company announced an acquisition of Pharmaq, a developer of aquaculture disease treatments.
Aftermath
The deal broadened Zoetis's international animal-health portfolio to include a stronger aquaculture offering.
2013
Zoetis initial public offeringProduct launchBackground
The new company required a public-market structure as Pfizer separated its animal-health business.
Action taken
Zoetis sold 86.1 million shares in an IPO and used part of the proceeds to help address Pfizer debt.
Aftermath
Pfizer initially retained approximately 83 percent of Zoetis, before completing the separation later in 2013.
IPO proceeds. approximately US$2.2 billion (February 1, 2013)
2012
Separate Pfizer Animal Health into ZoetisStrategyBackground
Pfizer was reviewing businesses outside its core human-pharmaceutical activities and sought to simplify its portfolio while raising capital and reducing debt.
Action taken
Pfizer created Zoetis as a separately branded animal-health company and prepared it for public ownership.
Aftermath
The business completed its IPO in 2013 and became fully independent after Pfizer distributed its retained stake.
Recent events
Zoetis announces acquisition of Performance Livestock Analytics[5]
Reported:
Zoetis announced the acquisition of Performance Livestock Analytics, a livestock-industry data and analytics technology company. Financial terms were not disclosed.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/zoetis · Editorial policy · How profiles are compiled